| Gene Symbol | APOE |
| Full Name | Apolipoprotein E |
| Chromosome | 19q13.32 |
| Target Class | Ligand |
| Function | It binds to the LDL receptor family to facilitate uptake of lipoprotein particles. |
| Mechanism of Action | Protein-protein interaction modulator or lipid metabolism enhancer |
| Druggability | Medium (0.47) |
| Clinical Stage | Phase II |
| Molecular Weight | 34 kDa |
| Pathways | Amyloid, Autophagy, Blood-Brain Barrier, Brain Lipid Metabolism, Cholesterol |
| GeneCards | APOE |
| Human Protein Atlas | APOE |
| Genotype | AD Risk |
| ε3/ε3 | Baseline (1x) |
| ε3/ε4 | ~3x increased |
| Associated Diseases | AD, AGING, ALS, ALZHEIMER, ALZHEIMER'S DISEASE, AMI |
| Known Drugs/Compounds | LIPOPROTEINS, Triacylglycerol, Lipid-Targeting Therapeutic Strategies |
| Interactions | LRP1, LDLR, LOX, IL6, SREBF1, PSEN2 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | APOE4-Specific Lipidation Enhancement Therapy Prime Editing Precision Correction of APOE4 to APO Selective APOE4 Degradation via Proteolysis Target (+11 more) |
| KG Connections | 4776 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |